Biochemistry of Hemostasis — MCQs
Activated protein C inhibits the clotting mechanism by inactivating which of the following clotting factors?
Von Willebrand disease involves a deficiency of which factor?
Which of the following statements is true regarding von Willebrand disease?
The clot formed after the coagulation cascade is not stable unless extensive cross-linking occurs. This is done by:
A patient on low-molecular-weight heparin suddenly develops a severe hemorrhage. What test would be most useful to assess the degree of anticoagulation?
Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?
Which of the following is not typically seen in Disseminated Intravascular Coagulation (DIC)?
A 34-year-old, G1P0, presents for genetic counseling at 12 weeks' gestation. The patient has two sisters and a brother; her father has hemophilia. Her siblings are not affected, but she has a nephew who is affected. What is the inheritance pattern of this disorder?
Which of the following is a sex-linked disorder?
Ferritin biosynthesis is regulated by the serum level of which substance?
Biochemistry of Hemostasis Indian Medical PG Practice Questions and MCQs
Question 1: Activated protein C inhibits the clotting mechanism by inactivating which of the following clotting factors?
- A. Factor Va and Factor VIIIa (Correct Answer)
- B. Factor III and Factor VIIIa
- C. Factor VIIIa and Factor IX
- D. Factor Va and Factor VII
Explanation: ***Factor Va and Factor VIIIa*** - **Activated protein C (APC)** functions as a natural anticoagulant by specifically inactivating the activated forms of **Factor V (Va)** and **Factor VIII (VIIIa)**. - By inactivating these cofactors, APC effectively downregulates the functioning of the **prothrombinase complex** and **tenase complex**, thereby slowing down thrombin generation and subsequent fibrin formation. *Factor III and Factor VIIIa* - **Factor III (tissue factor)** initiates the extrinsic coagulation pathway, but it is not directly inactivated by activated protein C. - While **Factor VIIIa** is a target of APC, the combination with Factor III makes this option incorrect. *Factor VIIIa and Factor IX* - **Factor VIIIa** is indeed inactivated by APC. - However, **Factor IX** (the inactive zymogen) and its activated form **Factor IXa** are not direct targets for inactivation by APC; Factor IXa remains active to participate in the tenase complex until its co-factor Factor VIIIa is inactivated. *Factor Va and Factor VII* - **Factor Va** is a known target for inactivation by APC. - **Factor VII** (the inactive zymogen) and its activated form **Factor VIIa** are not inactivated by APC; Factor VIIa plays a role in the initiation of coagulation by forming a complex with tissue factor.
Question 2: Von Willebrand disease involves a deficiency of which factor?
- A. Defect in platelet adhesion due to von Willebrand factor deficiency (Correct Answer)
- B. Defect in fibrin formation affecting clot stabilization
- C. Generalized defects involving small blood vessels
- D. Defect in clotting factors affecting secondary hemostasis
Explanation: ***Primary hemostasis*** - Von Willebrand disease primarily affects **primary hemostasis** due to defective or deficient **von Willebrand factor (vWF)**, which is crucial for platelet adhesion [1][3]. - This defect results in **increased bleeding tendencies**, exemplified by symptoms like easy bruising and prolonged bleeding from cuts [2]. *Secondary hemostasis* - Secondary hemostasis involves the **coagulation cascade**, not primarily affected in von Willebrand disease [3]. - Disorders related to secondary hemostasis typically involve factors like **factor VII, IX, or X**, unlike the vWF defect seen here [3]. *Generalized defects involving small vessels* - Generalized defects imply broader issues affecting the **microcirculation**, which is not the primary issue in von Willebrand disease. - While small vessel bleeding can occur, it is not specific to this condition as it does not primarily involve the **platelet aggregation** defect [1]. *Clot stabilization and resorption* - Clot stabilization and resorption primarily involve factors such as **fibrinogen** and cross-linking factors, rather than vWF. - Von Willebrand disease specifically impacts the **platelet function** and does not directly relate to stabilization processes once the clot has formed [1][3].
Question 3: Which of the following statements is true regarding von Willebrand disease?
- A. Factor VIII levels are always normal.
- B. Platelet count is consistently decreased.
- C. Bleeding time is prolonged due to impaired platelet adhesion. (Correct Answer)
- D. Activated partial thromboplastin time (aPTT) is always normal.
Explanation: Normal prothrombin time (PT) - In von Willebrand disease, **PT remains normal**, which indicates that the extrinsic pathway of coagulation is unaffected [1]. - This disorder primarily affects **platelet function** and vWF levels, not prothrombin time. *Platelet count may be decreased in some cases* - While platelet count can be low, it is not a consistent finding in von Willebrand disease; often, **platelet count is normal**. - The disorder primarily involves **qualitative abnormalities** in platelets due to impaired vWF function, rather than quantitative [3]. *Bleeding time is prolonged* - Bleeding time is typically **prolonged** in von Willebrand disease, which reflects platelet dysfunction, but this statement does not correctly state its context. - The disease affects **hemostasis**, leading to increased bleeding tendencies rather than maintaining normal bleeding times. *Normal activated partial thromboplastin time (aPTT)* - In von Willebrand disease, **aPTT may be prolonged** due to the deficiency of factor VIII, which is carried by vWF [2]. - The presence of normal aPTT does not reflect the disease's impact on the intrinsic pathway of coagulation.
Question 4: The clot formed after the coagulation cascade is not stable unless extensive cross-linking occurs. This is done by:
- A. Plasmin
- B. Factor XIII (Correct Answer)
- C. Thrombin
- D. High molecular weight kininogen
Explanation: ***Factor XIII*** - **Factor XIIIa** (activated Factor XIII) is a **transglutaminase** that catalyzes the formation of **covalent bonds** between **fibrin monomers**, specifically between lysine and glutamine residues. - This cross-linking strengthens the **fibrin clot**, making it more resistant to mechanical stress and proteolytic degradation. *Plasmin* - **Plasmin** is an enzyme responsible for **fibrinolysis**, meaning it breaks down fibrin clots. - It acts to remodel and **dissolve clots**, not to stabilize them. *Thrombin* - **Thrombin** (Factor IIa) is a key enzyme in the coagulation cascade that converts **fibrinogen into fibrin monomers**. - While essential for clot formation, thrombin's primary role is to create the fibrin mesh, not to extensively cross-link it for stability. *High molecular weight kininogen* - **High molecular weight kininogen (HMWK)** is a cofactor in the **intrinsic coagulation pathway**, facilitating the activation of Factor XII and prekallikrein. - It is involved in initiating coagulation but does not directly participate in the cross-linking and stabilization of the fibrin clot.
Question 5: A patient on low-molecular-weight heparin suddenly develops a severe hemorrhage. What test would be most useful to assess the degree of anticoagulation?
- A. Stop LMWH immediately (Correct Answer)
- B. Transfuse blood products
- C. Administer protamine sulfate
- D. Consider specific reversal agents
Explanation: ***Stop LMWH immediately*** - The immediate priority in severe hemorrhage due to **low-molecular-weight heparin (LMWH)** is to cease further administration of the anticoagulant. [1] - This prevents worsening of the bleeding by halting the delivery of more drug that could contribute to the **anticoagulant effect**, thus allowing natural clotting mechanisms to begin recovery. [1] *Administer protamine sulfate* - While **protamine sulfate** is a reversal agent for LMWH, its efficacy is only partial (about 60-75% neutralization of anti-Xa activity) compared to its effect on unfractionated heparin. - Therefore, it is a secondary step after stopping the drug itself and may not fully reverse the severe hemorrhage. *Transfuse blood products* - **Transfusion of blood products** (e.g., packed red blood cells, fresh frozen plasma, platelets) addresses the consequences of severe hemorrhage (e.g., anemia, coagulopathy) but does not directly neutralize the anticoagulant effect of LMWH. - This is a supportive measure, crucial for managing blood loss and maintaining hemodynamic stability, but not the primary action to stop the drug's effect. *Consider specific reversal agents* - **Specific reversal agents** for LMWH itself are limited; protamine sulfate is the primary option, albeit with partial efficacy. - Newer agents for direct oral anticoagulants might be considered in other contexts, but for LMWH, stopping the drug is the most immediate and universally applicable action.
Question 6: Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?
- A. Factor VII (Correct Answer)
- B. Factor IX
- C. Factor X
- D. Prothrombin (Factor 2)
Explanation: ***Factor VII*** - Factor VII has the **shortest half-life** (approximately 6 hours) among the vitamin K-dependent clotting factors, meaning its functional activity decreases **most rapidly** after starting warfarin therapy. - Warfarin inhibits vitamin K epoxide reductase, preventing gamma-carboxylation of **all vitamin K-dependent factors** (II, VII, IX, X). However, Factor VII's short half-life means pre-existing functional Factor VII is depleted first. - This is why **PT/INR** (which measures the extrinsic pathway dependent on Factor VII) rises before aPTT in warfarin therapy. - Reduced gamma-carboxylation impairs Factor VII's ability to bind calcium and phospholipids, essential for its activation in the extrinsic coagulation pathway. *Factor IX* - Factor IX is a **vitamin K-dependent factor** affected by warfarin, but its longer half-life (approximately 24 hours) means functional activity decreases more slowly than Factor VII. - It plays a key role in the **intrinsic coagulation pathway**. *Factor X* - Factor X is a **vitamin K-dependent clotting factor** whose gamma-carboxylation is inhibited by warfarin. - Its half-life (approximately 40 hours) is longer than Factor VII, resulting in a **slower decline in functional activity**. *Prothrombin (Factor II)* - Prothrombin (Factor II) is a **vitamin K-dependent factor** affected by warfarin. - It has the **longest half-life** (60-72 hours) among vitamin K-dependent factors, meaning its functional levels decrease most slowly after initiating warfarin therapy.
Question 7: Which of the following is not typically seen in Disseminated Intravascular Coagulation (DIC)?
- A. Thrombocytopenia
- B. PT elevation
- C. Fibrinogen decreased
- D. Normal aPTT (Correct Answer)
Explanation: ***Normal APTT*** - In Disseminated Intravascular Coagulation (**DIC**), **APTT** is typically **prolonged** due to consumption of clotting factors [1]. - The presence of normal APTT indicates that coagulation pathways are not significantly affected, which is contrary to what is seen in DIC. *Fibrinogen decreased* - **Decreased fibrinogen levels** are common in DIC, reflecting its consumption during the coagulation process [1]. - This depletion is linked to the increased clotting and is a hallmark of DIC, making this statement false in the context of the question. *Thrombocytopenia* - **Thrombocytopenia** occurs in DIC as platelets are consumed during the formation of microclots [1]. - A significant drop in platelet count is a key feature of DIC, therefore this statement does not align with the "except" clause. *PT elevation* - Prothrombin Time (**PT**) is usually **elevated** in DIC due to the consumption of clotting factors [1]. - This reflects the ongoing activation of the coagulation cascade, supporting the exclusion in the question context. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 625-626.
Question 8: A 34-year-old, G1P0, presents for genetic counseling at 12 weeks' gestation. The patient has two sisters and a brother; her father has hemophilia. Her siblings are not affected, but she has a nephew who is affected. What is the inheritance pattern of this disorder?
- A. X-linked inheritance (Correct Answer)
- B. Autosomal recessive
- C. Mitochondrial inheritance
- D. Multifactorial inheritance
Explanation: ***X-linked inheritance*** - Hemophilia is an **X-linked recessive disorder** - An affected father passes his X chromosome mutation to **all daughters**, making them **obligate carriers** (not affected but carry the gene) - The affected nephew (son of patient's sister) confirms the patient's sister is a carrier who passed the affected X chromosome to her son - Classic pattern: affected males, carrier females, skips generations through female carriers *Autosomal recessive* - Would require both parents to be carriers for offspring to be affected - An affected father would pass one mutant allele to all children, but this wouldn't make daughters obligate carriers unless mother also carried the gene - Pattern of father → carrier daughter → affected grandson is not typical of autosomal recessive inheritance *Mitochondrial inheritance* - Only transmitted from mother to **all children** regardless of gender - Affected father **cannot** pass mitochondrial disorders to offspring - Would show maternal transmission pattern with all children of affected mothers being affected *Multifactorial inheritance* - Involves combination of multiple genes and environmental factors - Does not follow clear Mendelian pattern - The distinct single-gene pattern (affected father, carrier daughters, affected male grandchild) indicates X-linked recessive, not multifactorial
Question 9: Which of the following is a sex-linked disorder?
- A. Hemophilia (Correct Answer)
- B. Neurofibromatosis
- C. Klinefelter's syndrome
- D. Thalassemia
Explanation: ***Hemophilia*** - Hemophilia is an **X-linked recessive disorder**, meaning the gene responsible is located on the X chromosome. - Males are predominantly affected because they have only one X chromosome, so a single copy of the mutated gene is sufficient to cause the disease. *Neurofibromatosis* - Neurofibromatosis is an **autosomal dominant disorder**, meaning a single copy of the mutated gene on a non-sex chromosome is enough to cause the condition. - It affects males and females equally and is characterized by tumors along nerves and skin changes. *Klinefelter's syndrome* - Klinefelter's syndrome is a **chromosomal disorder** resulting from an extra X chromosome in males (XXY), not a single gene mutation on a sex chromosome. - While it involves sex chromosomes, it's categorized as a **sex chromosome aneuploidy** rather than a sex-linked disorder in the traditional genetic sense. *Thalassemia* - Thalassemia is an **autosomal recessive disorder**, meaning it requires two copies of the mutated gene (one from each parent) on non-sex chromosomes to manifest. - It affects the production of hemoglobin and impacts males and females equally.
Question 10: Ferritin biosynthesis is regulated by the serum level of which substance?
- A. Ceruloplasmin
- B. Hepcidin
- C. Iron (Correct Answer)
- D. Transferrin
Explanation: ### Explanation **Correct Option: C. Iron** Ferritin is the primary intracellular storage form of iron. Its biosynthesis is regulated at the **translational level** by the availability of free intracellular iron. This occurs via the **Iron Response Element (IRE)** and **Iron Regulatory Protein (IRP)** mechanism: * **Low Iron:** IRPs bind to the IRE located at the 5' untranslated region (UTR) of ferritin mRNA, physically blocking translation to prevent unnecessary storage. * **High Iron:** Iron binds to IRPs, causing them to dissociate from the mRNA. This allows the ribosome to translate the mRNA, increasing ferritin synthesis to safely sequester the excess iron. **Analysis of Incorrect Options:** * **A. Ceruloplasmin:** This is a copper-containing ferroxidase that converts Fe²⁺ to Fe³⁺ to facilitate iron binding to transferrin. It does not directly regulate ferritin synthesis. * **B. Hepcidin:** Known as the "Master Regulator of Iron Homeostasis," hepcidin controls systemic iron levels by degrading **ferroportin** (the iron exporter). While it influences iron availability, it does not directly regulate the biosynthesis of the ferritin protein. * **D. Transferrin:** This is the transport protein for iron in the plasma. While transferrin levels are inversely related to iron stores, it is a carrier, not a regulator of ferritin production. **High-Yield Clinical Pearls for NEET-PG:** * **Translational Control:** Ferritin is a classic example of post-transcriptional/translational regulation (unlike most proteins regulated at the transcriptional level). * **Serum Ferritin:** It is the **best initial test** and most sensitive marker for diagnosing **Iron Deficiency Anemia** (levels <15 ng/mL). * **Acute Phase Reactant:** Ferritin levels rise during inflammation, infection, or malignancy, which can mask an underlying iron deficiency. * **Hemosiderin:** This is an insoluble form of partially denatured ferritin, found in states of iron overload (e.g., Hemochromatosis).
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free